8-K: Liquidia Corporation Announces FDA Update on YUTREPIA New Drug Application

Liquidia Corporation has received an update from the FDA regarding the review of its New Drug Application for YUTREPIA, with the FDA confirming the process for adding the PH-ILD indication as an amendment.

Summary

• Liquidia Corporation announced that the FDA is confirming the process for adding the PH-ILD indication to the New Drug Application (NDA) for YUTREPIA.
• The FDA will not meet the previously set PDUFA goal date of January 24, 2024, for issuing an action letter, and the review is ongoing.
• The FDA did not request any additional clinical data to support the NDA.
• Liquidia is preparing for the final FDA approval of YUTREPIA to treat both PAH and PH-ILD patients following the expiration of regulatory exclusivity for Tyvaso on March 31, 2024.
• YUTREPIA has already met the regulatory standards for quality, safety, and efficacy for the treatment of PAH, as indicated by the tentative approval issued on November 5, 2021.
• The company believes that final FDA approval for YUTREPIA will not be subject to any statutory 30-month stay arising from the New Hatch-Waxman Litigation.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the delay in the PDUFA goal date, but positive aspects include no request for additional data and the company's preparation for final approval. The ongoing litigation adds a layer of uncertainty.

Positives

• The FDA is actively working with Liquidia to add the PH-ILD indication to the YUTREPIA NDA.
• No additional clinical data was requested by the FDA, suggesting the existing data is sufficient.
• YUTREPIA has already met regulatory standards for quality, safety, and efficacy for PAH.
• The company anticipates final approval for both PAH and PH-ILD indications.
• Liquidia believes that the final approval will not be delayed by a 30-month stay.

Negatives

• The FDA will not meet the previously set PDUFA goal date of January 24, 2024.
• The review of the NDA is still ongoing, introducing uncertainty about the final approval timeline.

Risks

• The ongoing review by the FDA introduces uncertainty regarding the final approval timeline for YUTREPIA.
• There is ongoing litigation related to patent infringement, which could potentially impact the commercialization of YUTREPIA.
• The company operates in a competitive and rapidly changing environment, which introduces inherent risks.

Future Outlook

Liquidia is preparing for the final FDA approval of YUTREPIA to treat both PAH and PH-ILD patients following the expiration of regulatory exclusivity for Tyvaso on March 31, 2024.

Management Comments

• Dr. Roger Jeffs, Chief Executive Officer, said: 'We are in active communication with the FDA regarding the process we followed to amend our NDA to add PH-ILD to the labeled indication.'
• Dr. Roger Jeffs, Chief Executive Officer, said: 'Whether the NDA is amended or supplemented, we will continue to prepare for the final FDA approval of YUTREPIA to treat both PAH and PH-ILD patients following the expiration of regulatory exclusivity for Tyvaso on March 31, 2024.'
• Dr. Roger Jeffs, Chief Executive Officer, said: 'As communicated by the tentative approval to treat PAH, YUTREPIA has already met the regulatory standards for quality, safety and efficacy.'
• Dr. Roger Jeffs, Chief Executive Officer, said: 'We remain committed to addressing the unmet needs across all patients whose lives may be improved by the unique benefits of YUTREPIA.'

Industry Context

This announcement is significant in the context of the pulmonary hypertension market, as YUTREPIA is positioned as a potential competitor to Tyvaso, particularly after Tyvaso's exclusivity expires. The addition of the PH-ILD indication could expand YUTREPIA's market reach.

Comparison to Industry Standards

• The tentative approval for PAH indicates that YUTREPIA has met the FDA's standards for quality, safety, and efficacy, which is a benchmark for new drug approvals in the pharmaceutical industry.
• The ongoing litigation with United Therapeutics is a common occurrence in the pharmaceutical industry, particularly with patent disputes, and Liquidia's approach to addressing these challenges is consistent with industry practices.
• The use of PRINT technology for drug particle engineering is a novel approach that could differentiate YUTREPIA from other inhaled treprostinil products, such as Tyvaso.

Legal Proceedings

• Liquidia is involved in ongoing patent litigation with United Therapeutics.
• The company filed a request to set aside an injunction related to the original Hatch-Waxman litigation.
• The CAFC affirmed the PTAB decision that found all claims of the 793 Patent to be unpatentable.
• UTHR filed a second complaint for patent infringement, with the 327 Patent being the sole remaining patent at issue.

Stakeholder Impact

• Shareholders may experience uncertainty due to the delay in the PDUFA goal date and ongoing litigation.
• Patients with PAH and PH-ILD may benefit from the potential approval of YUTREPIA.
• Employees of Liquidia are likely focused on the regulatory approval process and litigation.

Next Steps

• Liquidia will continue to communicate with the FDA regarding the NDA amendment process.
• Liquidia will continue to prepare for the final FDA approval of YUTREPIA.
• Liquidia will continue to address the ongoing patent litigation.

Key Dates

Keywords

YUTREPIA, treprostinil, pulmonary arterial hypertension, PAH, pulmonary hypertension, PH-ILD, FDA, New Drug Application, NDA, PDUFA, Liquidia, patent litigation